PDF(Pubmed)
Abstract：
UNASSIGNED: Levetiracetam (LEV) is commonly prescribed for epilepsy management. However, neuropsychiatric disorders (NPDs) are concerning adverse effects that may result in medication discontinuation. This study aims to examine the incidence and factors influencing LEV associated NPDs in adult patients aged 50 years and above.
UNASSIGNED: A retrospective analysis was conducted on patients aged 50 years and above prescribed LEV between 2010 and 2020, with at least one follow-up appointment six months post-treatment initiation. The incidence of new-onset or aggravated NPDs and variables potentially influencing this risk were examined. Independent t-test, chi-squared, and Fisher\'s exact test were used, in addition to univariate and multivariate logistic regression.
UNASSIGNED: The study included 100 patients with a mean age at LEV start of 63.31 years (SD = 16.48). Neuropsychiatric symptoms were observed in 6 (6.0%) patients. Factors associated with new-onset NPDs were younger age at epilepsy diagnosis (p=0.005), younger age at LEV start (p=0.004), and concurrent use of Carbamazepine/Oxcarbazepine (p=0.004). On multivariate analysis, only the association with Carbamazepine/Oxcarbazepine remained significant (OR 14.62, 95% CI 1.86-114.70, p=0.011).
UNASSIGNED: The findings indicate that the incidence of NPDs in elderly patients is relatively low (6%). Further research with larger samples is needed in comparison with a younger sample as a control group to confirm these findings.
UNASSIGNED: A retrospective analysis was conducted on patients aged 50 years and above prescribed LEV between 2010 and 2020, with at least one follow-up appointment six months post-treatment initiation. The incidence of new-onset or aggravated NPDs and variables potentially influencing this risk were examined. Independent t-test, chi-squared, and Fisher\'s exact test were used, in addition to univariate and multivariate logistic regression.
UNASSIGNED: The study included 100 patients with a mean age at LEV start of 63.31 years (SD = 16.48). Neuropsychiatric symptoms were observed in 6 (6.0%) patients. Factors associated with new-onset NPDs were younger age at epilepsy diagnosis (p=0.005), younger age at LEV start (p=0.004), and concurrent use of Carbamazepine/Oxcarbazepine (p=0.004). On multivariate analysis, only the association with Carbamazepine/Oxcarbazepine remained significant (OR 14.62, 95% CI 1.86-114.70, p=0.011).
UNASSIGNED: The findings indicate that the incidence of NPDs in elderly patients is relatively low (6%). Further research with larger samples is needed in comparison with a younger sample as a control group to confirm these findings.
摘要：
■左乙拉西坦（LEV）通常用于癫痫治疗。然而,神经精神疾病(NPDs)涉及可能导致停药的不良反应.本研究旨在研究50岁及以上成人患者LEV相关NPDs的发生率和影响因素。
■在2010年至2020年期间，对50岁及以上规定LEV的患者进行了回顾性分析，并在治疗开始后六个月进行了至少一次随访。检查了新发或加重的NPDs的发生率以及可能影响该风险的变量。独立t检验,卡方，使用了费希尔的精确检验，除了单变量和多变量逻辑回归。
■该研究包括100名患者，LEV开始时平均年龄为63.31岁（SD=16.48）。6例(6.0%)患者出现神经精神症状。与新发NPDs相关的因素是癫痫诊断时年龄较小（p=0.005），LEV开始时年龄较小（p=0.004），同时使用卡马西平/奥卡西平（p=0.004）。在多变量分析中，只有与卡马西平/奥卡西平的相关性仍然显著(OR14.62,95%CI1.86-114.70,p=0.011).
■研究结果表明，老年患者中NPDs的发生率相对较低（6％）。与作为对照组的年轻样本相比，需要对更大样本进行进一步研究以证实这些发现。
■在2010年至2020年期间，对50岁及以上规定LEV的患者进行了回顾性分析，并在治疗开始后六个月进行了至少一次随访。检查了新发或加重的NPDs的发生率以及可能影响该风险的变量。独立t检验,卡方，使用了费希尔的精确检验，除了单变量和多变量逻辑回归。
■该研究包括100名患者，LEV开始时平均年龄为63.31岁（SD=16.48）。6例(6.0%)患者出现神经精神症状。与新发NPDs相关的因素是癫痫诊断时年龄较小（p=0.005），LEV开始时年龄较小（p=0.004），同时使用卡马西平/奥卡西平（p=0.004）。在多变量分析中，只有与卡马西平/奥卡西平的相关性仍然显著(OR14.62,95%CI1.86-114.70,p=0.011).
■研究结果表明，老年患者中NPDs的发生率相对较低（6％）。与作为对照组的年轻样本相比，需要对更大样本进行进一步研究以证实这些发现。
